| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $134,729,316 | 58 | 100 |
| PYOTT DAVID E I | director | 0 | $0 | 1 | $2.22M | $-2.22M |
| SHARP PHILLIP A | director | 0 | $0 | 1 | $3.09M | $-3.09M |
| Tanguler Tolga | EVP, Chief Commercial Officer | 0 | $0 | 6 | $3.61M | $-3.61M |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 0 | $0 | 8 | $5.61M | $-5.61M |
| BONNEY MICHAEL W | director | 0 | $0 | 2 | $8.19M | $-8.19M |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 0 | $0 | 10 | $9.94M | $-9.94M |
| Reitan Colleen F | director | 0 | $0 | 3 | $13.21M | $-13.21M |
| Garg Pushkal | CMO & EVP Dev & Med Affairs | 0 | $0 | 15 | $24.87M | $-24.87M |
| Ausiello Dennis A | director | 0 | $0 | 2 | $26.1M | $-26.1M |
| Greenstreet Yvonne | Chief Executive Officer | 0 | $0 | 10 | $37.89M | $-37.89M |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Alnylam Pharmaceuticals, Inc. have bought $0 and sold $134.73M worth of Alnylam Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Alnylam Pharmaceuticals, Inc. have bought $10,363 and sold $53.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4 shares for transaction amount of $1,211 was made by Reitan Colleen F (director) on 2024‑10‑17.
| 2026-01-13 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 2,290 0.0017% | $370.33 | $848,065 | -1.03% | |
| 2026-01-12 | Sale | Greenstreet Yvonne | Chief Executive Officer | 9,577 0.0071% | $362.86 | $3.48M | +2.16% | |
| 2026-01-12 | Sale | Poulton Jeffrey V. | EVP, Chief Financial Officer | 2,688 0.002% | $362.42 | $974,197 | +2.16% | |
| 2026-01-12 | Sale | Poulton Jeffrey V. | EVP, Chief Financial Officer | 2,780 0.0021% | $362.87 | $1.01M | +2.16% | |
| 2026-01-12 | Sale | Tanguler Tolga | EVP, Chief Commercial Officer | 1,510 0.0011% | $362.87 | $547,927 | +2.16% | |
| 2026-01-12 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 1,510 0.0011% | $362.87 | $547,927 | +2.16% | |
| 2026-01-12 | Sale | Garg Pushkal | EVP Chief R&D | 1,268 0.0009% | $361.46 | $458,333 | +2.16% | |
| 2026-01-12 | Sale | Garg Pushkal | EVP Chief R&D | 1,510 0.0011% | $362.87 | $547,929 | +2.16% | |
| 2025-11-17 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 12,128 0.009% | $452.18 | $5.48M | -12.18% | |
| 2025-11-13 | Sale | Greenstreet Yvonne | Chief Executive Officer | 10,000 0.0075% | $451.27 | $4.51M | -10.19% | |
| 2025-11-12 | Sale | Greenstreet Yvonne | Chief Executive Officer | 15,650 0.0121% | $453.69 | $7.1M | -9.89% | |
| 2025-10-03 | Sale | Garg Pushkal | EVP Chief R&D | 3,022 0.0023% | $451.48 | $1.36M | -3.10% | |
| 2025-10-02 | Sale | Greenstreet Yvonne | Chief Executive Officer | 8,924 0.0067% | $452.05 | $4.03M | -3.97% | |
| 2025-10-02 | Sale | Poulton Jeffrey V. | EVP, Chief Financial Officer | 3,821 0.0029% | $452.05 | $1.73M | -3.97% | |
| 2025-10-02 | Sale | Tanguler Tolga | EVP, Chief Commercial Officer | 1,405 0.0011% | $452.05 | $635,126 | -3.97% | |
| 2025-10-02 | Sale | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 2,441 0.0018% | $452.05 | $1.1M | -3.97% | |
| 2025-10-02 | Sale | Garg Pushkal | EVP Chief R&D | 2,937 0.0022% | $452.05 | $1.33M | -3.97% | |
| 2025-09-09 | Sale | Reitan Colleen F | director | 10,372 0.0076% | $460.86 | $4.78M | -6.47% | |
| 2025-09-09 | Sale | Reitan Colleen F | director | 18,000 0.0133% | $467.60 | $8.42M | -6.47% | |
| 2025-08-29 | Sale | Tanguler Tolga | EVP, Chief Commercial Officer | 3,474 0.0027% | $448.37 | $1.56M | +1.11% |
| Greenstreet Yvonne | Chief Executive Officer | 78411 0.0594% | $28.15M | 0 | 31 | |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | 57465 0.0435% | $20.63M | 0 | 14 | |
| Tanguler Tolga | EVP, Chief Commercial Officer | 29728 0.0225% | $10.67M | 0 | 15 | |
| Garg Pushkal | EVP Chief R&D | 22511 0.017% | $8.08M | 0 | 25 | |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | 21264 0.0161% | $7.63M | 0 | 14 | |
| BONNEY MICHAEL W | director | 16804 0.0127% | $6.03M | 2 | 4 | <0.0001% |
| Ausiello Dennis A | director | 911 0.0007% | $327,044.45 | 0 | 12 | |
| Reitan Colleen F | director | 775 0.0006% | $278,221.13 | 2 | 3 | <0.0001% |
| PYOTT DAVID E I | director | 136 0.0001% | $48,823.32 | 1 | 2 | +45.98% |
| SHARP PHILLIP A | director | 0 0% | $0 | 2 | 15 | +68.46% |
| Sanofi | 10 percent owner | 10554134 7.9887% | $3.79B | 6 | 0 | +18.68% |
| NOVARTIS AG | 10 percent owner | 4051002 3.0663% | $1.45B | 3 | 1 | <0.0001% |
| Westphal Christoph H | director, 10 percent owner | 300170 0.2272% | $107.76M | 1 | 0 | +16.38% |
| CHP II LP | 10 percent owner | 232500 0.176% | $83.47M | 1 | 0 | +16.38% |
| MARAGANORE JOHN | Chief Executive Officer | 214765 0.1626% | $77.1M | 9 | 42 | +49.04% |
| Abingworth Management LTD | 10 percent owner | 155367 0.1176% | $55.78M | 2 | 6 | +44.17% |
| Berriman John E | director | 155367 0.1176% | $55.78M | 1 | 0 | +16.38% |
| Greene Barry E | President | 70343 0.0532% | $25.25M | 7 | 18 | +53.61% |
| POLARIS VENTURE MANAGEMENT CO III LLC | 10 percent owner | 30384 0.023% | $10.91M | 0 | 23 | |
| Vaishnaw Akshay | President | 22774 0.0172% | $8.18M | 0 | 36 | |
| CLARKE JOHN K | director | 8891 0.0067% | $3.19M | 1 | 2 | |
| SCHULMAN AMY W | director | 8436 0.0064% | $3.03M | 0 | 2 | |
| ATLAS VENTURE FUND V LP | 10 percent owner | 6557 0.005% | $2.35M | 2 | 2 | +8.19% |
| KEATING LAURIE | EVP, Chief Legal Officer | 5132 0.0039% | $1.84M | 1 | 17 | +78.8% |
| Franchini Indrani Lall | EVP, CLO & Secretary | 4133 0.0031% | $1.48M | 0 | 4 | |
| Reid Laurence | SVP, Chief Business Officer | 3905 0.003% | $1.4M | 1 | 7 | +41.4% |
| Barrett Peter | director | 2647 0.002% | $950,259.77 | 2 | 9 | +8.19% |
| PAUL STEVEN M | 2526 0.0019% | $906,821.37 | 1 | 3 | +10.44% | |
| Gros David-Alexandre C | SVP, Chief Business Officer | 1000 0.0008% | $358,995.00 | 1 | 0 | <0.0001% |
| STARR KEVIN P | director | 0 0% | $0 | 0 | 6 | |
| SCHIMMEL PAUL | director | 0 0% | $0 | 2 | 15 | +27.77% |
| Fanucci Marsha | director | 0 0% | $0 | 1 | 2 | +41.4% |
| VINCENT JAMES L | director | 0 0% | $0 | 0 | 5 | |
| Allen Patricia L | VP of Finance and Treasurer | 0 0% | $0 | 0 | 2 | |
| Mason Michael | VP, Finance and Treasurer | 0 0% | $0 | 0 | 13 |
$961,890,236 | 276 | 22.46% | $20.85B | |
$211,610,344 | 91 | 38.45% | $11.39B | |
$2,765,836 | 72 | 20.00% | $10.49B | |
$2,449,191,716 | 58 | 16.50% | $75.71B | |
$11,789,714 | 49 | 14.35% | $34.43B | |
Alnylam Pharmaceuticals, Inc. (ALNY) | $323,530,732 | 48 | 29.90% | $47.43B |
$88,307,390 | 38 | -1.70% | $10.29B | |
$19,233,721 | 36 | 70.14% | $11.79B | |
$13,655,378 | 35 | 17.13% | $21.03B | |
$15,836,193 | 25 | 17.98% | $113.16B | |
$415,090,639 | 19 | -14.04% | $14.7B | |
$143,065,458 | 17 | 8.01% | $23.25B | |
$152,272,932 | 16 | -10.78% | $17.17B | |
$627,701,115 | 15 | 145.68% | $12.69B | |
$284,820 | 10 | 45.67% | $12.36B | |
$948,235 | 8 | 15.56% | $10.7B | |
$40,276,273 | 4 | 34.57% | $16.09B | |
$36,900,000 | 3 | -9.12% | $10.93B | |
$999,989 | 1 | 262.16% | $16.35B |
| Increased Positions | 495 | +74.1% | 15M | +11.53% |
| Decreased Positions | 289 | -43.26% | 16M | -12% |
| New Positions | 213 | New | 2M | New |
| Sold Out Positions | 50 | Sold Out | 595,662 | Sold Out |
| Total Postitions | 874 | +30.84% | 132M | -0.47% |
| Fmr Llc | $6.71M | 12.7% | 16.77M | +961,104 | +6.08% | 2025-09-30 |
| Capital World Investors | $6.58M | 12.45% | 16.43M | -370,754 | -2.21% | 2025-09-30 |
| Vanguard Group Inc | $5.43M | 10.28% | 13.57M | +268,313 | +2.02% | 2025-09-30 |
| Blackrock, Inc. | $3.96M | 7.5% | 9.9M | -76,562 | -0.77% | 2025-09-30 |
| Capital Research Global Investors | $2.89M | 5.47% | 7.22M | +31,184 | +0.43% | 2025-09-30 |
| Jpmorgan Chase & Co | $1.82M | 3.44% | 4.54M | +2M | +120.36% | 2025-09-30 |
| State Street Corp | $1.23M | 2.33% | 3.08M | -91,630 | -2.89% | 2025-09-30 |
| Baillie Gifford & Co | $1.12M | 2.11% | 2.79M | -242,535 | -8% | 2025-09-30 |
| Geode Capital Management, Llc | $1M | 1.89% | 2.5M | +100,472 | +4.19% | 2025-09-30 |
| Dodge & Cox | $928,887.00 | 1.76% | 2.32M | -875,866 | -27.4% | 2025-09-30 |